EHD2 expression and clinical significance in non-small cell lung cancer
10.3969/j.issn.1006-5725.2017.22.023
- VernacularTitle:EHD2在非小细胞肺癌中的表达及其临床意义
- Author:
Liting LV
1
;
Yifei LIU
;
Jun LIU
;
Ling GAI
;
Guoxin MAO
Author Information
1. 南通大学附属医院肿瘤化疗科
- Keywords:
non-small cell lung cancer;
EHD2;
Ki-67;
prognosis
- From:
The Journal of Practical Medicine
2017;33(22):3769-3772
- CountryChina
- Language:Chinese
-
Abstract:
Objective We studied the EHD2 expression level in NSCLC and its association with clinicopathological features and prognosis.Methods The EHD2 expression level in NSCLC was measured by Western blot in 4 pairs fresh tissues and immunohistochemistry on 91 parffin-embedded slices.These experiments were used to explore the relationship of EHD2 and Ki-67 in the clinical parameters,as well as the relationship with EHD2 and prognosis.Results Western blot showed EHD2 expression level was low in 4 pairs NSCLC tissues.The results by immunohistochemistry showed that the expression of EHD2 was higher in well-differentiated NSCLC tissues than that in poor-differentiated tissues,which was opposite to the Ki-67 expression.Statistical methods revealed that EHD2 protein in NSCLC was significantly correlated with histological grade,pTNM staging,tumor size,lymph node metastasis as well as Ki-67.Low EHD2 expression was correlated with poor prognosis.Conclusions The abnormal expression of EHD2 might be closely related to the initiation and progress of NSCLC.EHD2 might be an indicator of the prognosis of NSCLC,which could be a potential target for NSCLC therapy.
